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Objective. This study identiﬁed and quantiﬁed polycyclic aromatic hydrocarbons (PAHs) in electrocautery smoke during 40
peritonectomy procedures and investigated any correlations and/or diﬀerences between levels of PAHs and perioperative variables.
Methods. PAHs were measured in personal and stationary sampling by 40mm Millipore cassettes, for adsorption of both gaseous
and particle-bound PAHs. Results. All 16 USEPA priority pollutant PAHs were detected during peritonectomy procedures,
naphthalene being the most abundant. For the only two PAHs with Swedish occupational exposure limits (OELs), benzo[a]pyrene
and naphthalene, limits were never exceeded. Amount of bleeding was the only perioperative variable that correlated with levels of
PAHs. Conclusions. Low levels of PAHs were detected in electrocautery smoke during peritonectomy procedures, and an increased
amount of bleeding correlated with higher levels of PAHs. For evaluation of long-term health eﬀects, more studies are needed.
1.Introduction
The monopolar electrocautery (i.e., electrosurgical) device is
an essential surgical tool that is used to cut through tissue
andcoagulatebloodvessels[1]andtherebyreducebloodloss
and operative time. However, the smoke produced by the use
of the electrocautery device is often considered to have an
unpleasant smell and irritates the airways of the surgeons
and the operating room staﬀ [2–4]. Electrocautery smoke
has been shown to contain considerable amounts of ultraﬁne
particles (UFPs) [5, 6], indicating that the smoke may be
potentially harmful [7]. The relationship between UFPs and
polycyclic aromatic hydrocarbons (PAHs) has not yet been
established. Still, some suggest that PAHs are often adsorbed
to particles [8, 9], especially those PAHs of higher molecular
mass or with ﬁve fused aromatic rings or more. PAHs with
lowermassarepresentinthevaporphase[10].Thereareover
200 PAHs, and they are primarily the result of incomplete
combustion of organic material [10]. The International
Agency for Research on Cancer (IARC) classiﬁes PAHs into
diﬀerent groups depending on carcinogenicity [11]. Several
PAHs are carcinogenic in animal studies and may also be
carcinogenic to humans. Today, the most common site of
PAH-caused cancer is the lung [10].
Electrocauterization is an essential part of almost all sur-
gical treatments, especially when treating peritoneal carcino-
matosis (PC). PC is a fatal condition without extensive surgi-
cal treatment, that is, peritonectomy combined with hyper-
thermic intraperitoneal chemotherapy (HIPEC) [12]. How-
ever, the use of the electrocautery device during peritonec-
tomies produces a large amount of smoke and UFPs [6]. As
PAHs are a product of combustion [10] and may adsorb to
UFPs [8, 9], it is likely that electrocautery smoke also con-
tains PAHs. Studies of the amount of PAHs in the electro-
cautery smoke from surgical procedures are limited. The pri-
mary aim of this study was to identify and quantify the
United States Environmental Protection Agency’s (USEPA)
16 priority pollutant PAHs in electrocautery smoke during
peritonectomy procedures, and the secondary aim was to
study any correlations and/or diﬀerences between levels of
PAHs and perioperative variables (diagnosis, length of sur-
gery,amountofbleeding,peritonealcancerindex(PCI),type
of anaesthesia, and type of chemotherapy).2 Journal of Environmental and Public Health
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Figure 1: The peritoneal cancer index (PCI). This index combines size and distribution parameters to obtain a numerical score. The lesion
size scores (0–3) in each of the abdominopelvic regions (n = 13) are summed to give the peritoneal cancer index (range 0–39) [13]. This
graphic is published by permission from Dr. P. H. Sugarbaker.
2. Methods
2.1. Description of Study Participants and Study Site. From
2009 to 2011, personal and stationary samplings of PAHs
in electrocautery smoke were performed during a total of
40peritonectomyproceduresatUppsalaUniversityHospital.
The regional ethics committees approved the study.
The 40 peritonectomies from which PAHs were collected
included 20 female and 20 male patients suﬀering from PC
from pseudomyxoma peritonei (PMP) (n = 22), colorectal
cancer (CRC) (n = 11), appendiceal cancer (n = 5), and
ovarian cancer (n = 2). All patients were anesthetized, either
with a combination of tiopental (Pentothal), rokuronium-
bromid (Esmeron), fentanyl, and isoﬂurane (PEF/ISO) (n =
32), or a combination of propofol (Diprivan), rokuronium-
bromid (Esmeron), fentanyl, and isoﬂurane (DEF/ISO) (n =
8). All but three patients received HIPEC: cisplatin/doxo-
rubicin (n = 17), oxaliplatin/irinotecan (n = 13), or mito-
mycin C (n = 7).
Peritonectomy was performed as described by Sugar-
baker [12]. The peritonectomy procedure is a surgical inter-
ventionwiththeaimofremovingdisseminatingcancers,that
is, PC, from the abdomen [12]. Tumor load was recorded
according to the peritoneal cancer index (PCI) (range 1–39)
(Figure 1)[ 13], in order to assess tumor load in the abdo-
minal cavity. PCI is calculated by summing lesion size scores
(0–3) within the abdominopelvic regions (0–12) (maximum
3×13 = 39).
Theelectrocauterygeneratorusedduringthisstudywasa
VIO 300 D (ERBE, SN 11260962, Elektromedizin, T¨ ubingen,
Germany), set on a dry cut at a high voltage of 200/300 W.
When all macroscopic tumors have been removed,
HIPEC is distributed within the open abdomen for 30–90
minutes to annihilate any remaining microscopic tumors
[12], at an abdominal temperature of 41.5–43◦C[ 14]. The
chemotherapeutic drugs are circulated with the help of a
roller pump, and a heat exchanger is connected to the
circuit [13, 15] to warm the drugs. Additionally, two smoke
evacuatorsareplacedtowardstheopeningoftheplasticsheet
during the entire treatment, to remove any vapors from the
heated chemotherapeutic drugs.
Descriptive statistics regarding length of surgery, PCI,
andamountofbleedingforthe40peritonectomyprocedures
are presented in Table 1. In one procedure, data for PCI and
amount of bleeding are missing.
2.2. Environmental Sampling. Both personal and stationary
samplings of PAHs in electrocautery smoke were performed.
Samplings started at the beginning of the surgery and ended
when the abdomen was surgically closed. All 40 measure-
ments were performed in the same operating room, and the
same OR staﬀ assisted at all sampling occasions.
The operating room was 46m2 and had 20 air changes
per hour. Air quality parameters, such as relative air humi-
dity, temperature, and carbon dioxide (CO2), were con-
tinuously measured in the operating theatre during theJournal of Environmental and Public Health 3
Table 1: Perioperative variables: Length of surgery, PCI, and bleed-
ing in 40/39 peritonectomy procedures.
Perioperative variables Median Lower quartile Upper quartile
Length of surgery
(h:min) (n = 40) 10:14 7: 08 11:33
PCI (score) (n = 39) 20 11 30
Bleeding (mL) (n = 39) 500 100 900
h: hours, min: minutes, n: number, PCI: peritoneal cancer index, and mL:
milliliter.
procedures, using a Q-Trak instrument (Q-Trak, IAQ Moni-
tor, model 8550, TSI Incorporated). During all peritonec-
tomies, the mean relative air humidity in the operating room
was23.0%,thetemperaturewas21.7◦C,andtheaverageCO2
was 485ppm.
2.2.1. Personal Sampling. Personal sampling was performed
using a 40mm Millipore cassette ﬁxed near the surgeon’s
breathing zone. The cassette contained XAD adsorbent for
adsorption of gaseous PAHs and a glass-microﬁber Munktell
ﬁlter grade MG 160 for particle-bound PAHs. The cassette
also contained an internal standard (PAH-Mix 9 deuterated
“XA20950902CY” mix) from LGC Standards AB (Bor˚ as,
Sweden). The cassette was connected to an SKC AirChek
5000 XR pump (SKC Inc., PA, USA) with an airﬂow of 4.2
litres/min [16].
2.2.2.StationarySampling. StationarysamplingofPAHswas
performed using a 20mm wide smoke evacuating hose,
connected to a Smoke Plume Evacuation System IES 2
(ERBE, Type nr 10321-000, App nr C-2046, Elektromedizin,
T¨ ubingen, Germany) with a set eﬃciency of 100%. A minor
cut was made in the hose in order to insert and attach the
tube to the ﬁlter cassette, Millipore (40mm), which collected
smoke particles and gases evacuated ﬁve cm from the tip of
the electrocautery device. The cut in the hose was sealed with
tape to prevent leakage of the collected smoke.
2.3. Sample Analyses. The samples were sent to Alcontrol
Laboratories (Link¨ oping, Sweden) for analysis. Prior to the
analysis, XAD mass and the ﬁlter from the sample container
were transferred to a test tube and extracted in an ultrasonic
bath for 10 minutes. The extraction was repeated three times
with a total of 20mL of dichloromethane (DKM), which was
combined in a round ﬂask. The extract was then roto evapo-
rated and transferred to a test tube, was evaporated under
nitrogen gas and heat (30◦C), and then was ready foranalysis
[16].
Samples were analysed by gas chromatography (HP
6890)usingaDB5-MScolumn(3m ×0.25mm,0.25micron
stationary phase with (5% phenyl)-methylpolysiloxane)
f r o mA g i l e n tJ&W .H e l i u mw a su s e da st h ec a r r i e rg a s
with a constant ﬂow of 1.5mL/min. The injection tempera-
ture was set to 280◦C, and the injection volume was 1 micro-
liter. The oven program was set to 60◦Cf o r1 m i na n d
ramped at 8◦C/min to 310◦C. The ionization method on the
mass spectrometer (HP 5973) included electron impact of
interface temperature 310◦C and ion source temperature at
230◦C. The Quadrupole temperature was set to 150◦C, and
the selected ion-monitoring (SIM) mode was used. Iden-
tiﬁcation and quantiﬁcation were carried out against cali-
bration standards and with known concentrations using the
internal standard method [16].
2.4. Statistical Analyses. Any correlations between PAHs
from all 40 peritonectomy procedures and the perioperative
variables (length of surgery and amount of bleeding) were
determined using Spearman’s rank correlation coeﬃcient.
Furthermore, a multiple regression was executed to establish
possible predictors for the amount of bleeding among the
PAHs. Spearman’s rank correlation coeﬃcients were calcu-
lated for 20 of the 40 peritonectomies, measured on separate
ﬁlters, to detect any correlations between PAHs with single
procedures’ diagnosis, PCI, length of surgery, amount of
bleeding, type of anaesthesia, and type of chemotherapy.
Additionally, Mann-Whitney U test was used to look for
diﬀerences between PAHs in PMP versus CRC, PAHs in cis-
platin/doxorubicin versus oxaliplatin/irinotecan, and PAHs
in PCI < 19 versus ≥20 (CRC). A 2-sided P value of less than
0.05 was considered statistically signiﬁcant. Statistical ana-




electrocautery smoke were detected, but not in all samples.
In the 40 peritonectomy procedures, the most abundant
compound was naphthalene, detected in all but one sam-
ple. The most abundant PAHs, apart from naphthalene,
were phenanthrene (93%), ﬂuorene (63.3%), acenaphthene
(40%) and acenaphthylene (36.7%) in personal samples. In
stationary sampling, acenaphthylene was detected in 93.3%,
phenanthrene in 90%, acenaphthene in 90%, and ﬂuorene
in 83.3% of the samples. Geometric means (GM) and geo-
metric standard deviations (SDs) of PAHs (ng/m3)f o ra l l4 0
peritonectomy procedures are presented in Table 2.
3.2. Correlations between PAHs and Perioperative Variables.
There was no correlation between PAHs and length of
surgery in the 40 peritonectomy procedures. However, both
personal and stationary sampling of PAHs and amount of
bleeding correlated to some extent (Table 3), but possible
predictors for the amount of bleeding among the PAHs
were not found. Acenaphthene and ﬂuorene correlated with
the amount of bleeding in personal sampling, and ben-
zo[a]anthracene, benzo[a]pyrene, benzo[b]ﬂuoranthene,
chrysene/triphenylene, acenaphthylene, anthracene, ben-
zo[ghi]perylene, phenanthrene, ﬂuoranthene, ﬂuorene,
naphthalene, and pyrene correlated in stationary samplings.
Diagnosis, PCI, length of surgery, type of anesthesia, and
typeofchemotherapydidnotcorrelatewithPAHswithinthe
grouping of 20 procedures, sampled separately.4 Journal of Environmental and Public Health
Table 2: GM and GSD (ng/m3) of PAH in 40 peritonectomy pro-
cedures.
PAH GM GSD
Benzo[a]anthracene P/S 0.14/0.14 ±2.68/±2.51
Benzo[a]pyrene P/S 0.13/0.16 ±2.43/±2.92
Benzo[b]ﬂuoranthene P/S 0.16/0.21 ±3.20/±3.83
Benzo[k]ﬂuoranthene P/S 0.14/0.16 ±3.14/±3.06
Chrysene/triphenylene P/S 0.15/0.34 ±3.31/±6.00
Dibenzo[a,h]anthracene P/S 0.11/0.13 ±1.88/±2.95
Indenol[1,2,3-cd]pyrene P/S 0.12/0.12 ±2.25/±1.96
Acenaphthene P/S 0.49/6.24 ±8.46/±5.64
Acenaphthylene P/S 0.34/14.63 ±5.87/±5.71
Anthracene P/S 0.11/0.35 ±1.94/±5.40
Benzo[ghi]perylene P/S 0.12/0.16 ±2.15/±3.10
Phenanthrene P/S 4.07/6.27 ±3.16/±5.17
Fluoranthene P/S 0.19/0.58 ±3.99/±7.02
Fluorene P/S 0.90/5.18 ±7.07/±6.15
Naphthalene P/S 63.41/178.66 ±2.20/±9.32
Pyrene P/S 0.15/0.50 ±3.18/±6.84
PAH: polycyclic aromatic hydrocarbon, P: personal sampling, S: stationary
sampling, GM: geometric mean, GSD: geometric standard deviation.
3.3. Diﬀerences between PAHs and Perioperative Variables. A
statistical diﬀerence could only be found between phenan-
threne in PMP versus CRC (P = 0.04) and phenanthrene
in cisplatin/doxorubicin versus oxaliplatin/irinotecan (P =
0.04), in personal sampling. PAHs in PCI < 19 versus ≥20
(CRC) showed no statistical diﬀerences.
4. Discussion
All 16 PAHs could be detected in both personal and
stationary samplings, but the levels of the most carcinogenic
substances were low. However, higher levels of carcinogen
PAHs were detected in single procedures, indicating that
higher cumulative amounts were being inhaled by surgeons
and operating room staﬀs. Naphthalene was the most com-
mon PAH in both personal and stationary samplings of this
study.Noneofthemostabundantcompounds(naphthalene,
acenaphthylene, acenaphthene, phenanthrene, and ﬂuorene)
have been proven to be carcinogenic. However, naphthalene
is stated to be a possible human carcinogen [10, 11], and
single, high doses have caused bronchiolar necrosis in ani-
mals. Naphthalene is also embryotoxic to mice and rats and
causes cataractin mouse eyes, and phenanthrene may induce
skin reactions after dermal application [10]. Several sources
of both known and possible PAH carcinogens surround
humans every day [17–23] ;s o m ea r ep r o b a b l ec a u s e so fc a n -
cers [23–25], and some probably cause other diseases [26–
29].Anincreaseincancerhasbeennotedwhenhumanshave
been exposed to several PAH-containing mixtures. However,
itisdiﬃculttosaywhethertheincreasedependsonthePAHs
exclusively, or if the mixtures include other carcinogenic
compounds [10]. Additionally, PAHs may aﬀect fetal growth
[30, 31].
Interestingly, signiﬁcant correlations were demonstrated
betweenPAHsandamountofbleeding,withinbothpersonal
and stationary samplings. This has not been reported earlier.
Blood consists of blood cells, blood plasma (90% water
containing plasma proteins and electrolytes: sodium chlo-
ride, potassium, calcium, magnesium salts, and phosphates),
and other components [32]. It is possible that some blood
components are aﬀected by the heat from the electrocautery
devicewhencoagulatingabloodvesselandproducePAHs.In
addition, the levels of PAHs in patients’ blood before surgery
could diﬀer, for example, depending on whether they are
smokers or not [22, 23].
A statistical diﬀerence could only be found in personal
sampling between phenanthrene in PMP versus CRC, and
between phenanthrene in cisplatin/doxorubicin versus oxali-
platin/irinotecan. Most probably, this diﬀerence depends
on skewness within the groups compared due to limited
observations (n = 14, PMP versus n = 4C R C ,a n dn = 15,
cisplatin/doxorubicin versus n = 5 oxaliplatin/irinotecan).
Unfortunately, this is one of the consequences of studying
peritonectomy procedures consecutively, instead of sorting
them into groups of diagnosis, PCI, length of surgery, and
so forth, which may vary considerably. Among these proce-
dures, there may also be a problem of forming suﬃciently
large groups for statistical analysis. Nevertheless, this is the
ﬁrst study of its kind, and the main purpose of the inves-
tigation was to identify and quantify the 16 USEPA-recom-
mended PAHs in electrocautery smoke. Finding single high
levels of PAHs is, of course, important because of their
known or possible carcinogenicity [10, 11], but it may be
evenmore interesting to report cumulative levelsofPAHsfor
those who are exposed in their everyday work. In this study,
mixturesofPAHswerepresentthatareknowntoincreasethe
risk of cancer [10].
Among the most abundant PAHs in this study, naphtha-
lene has the lowest molecular mass, with two fused aromatic
rings, and acenaphthylene, acenaphthene, phenanthrene,
and ﬂuorene follow with three rings. The heavier PAHs, with
more aromatic rings, are not represented in this group. PAHs
may adsorb to particles [8, 9], especially PAHs with ﬁve rings
or more, whilst others vaporize [10]. Yamasaki et al. [33]
foundthatPAHincreasedwithambientairtemperature[33].
In an iron foundry (at a PAH source temperature of 600–
700◦C) of the PAHs in the vapor phase, 70% were four to
sevenrings[34].Whenusingtheelectrocauterydevice,tissue
temperature may reach 150–400◦C[ 35].
There are only occupational exposure limits (OELs) for
two PAHs in Sweden: benzo[a]pyrene 2µg/m3 LLV (level
limit value: an occupational exposure limit value for expo-
sure during one working day) and 20µg/m3 STV (short-
term value: reference period of 15 minutes); naphthalene
50mg/m3 LLV and 80mg/m3 STV [36]. In the USA, the per-
missible exposure limit (PEL) for benzo[a]pyrene is 0.2mg/
m3 and50mg/m3 fornaphthalene.Meanvaluesoftheresults
of the samplings of benzo[a]pyrene and naphthalene in this
studywerewellbelowtheSwedishOELs.Moreover,nosingle
value exceeded the limits of these PAHs.
The strength of this study is the homogeneity under
which the samplings were executed. During all 40 samplings,Journal of Environmental and Public Health 5
Table 3: Spearman rank correlations between PAHs and bleeding.
PAH
Bleeding in 40 peritonectomies
Correlations −95% CI +95% CI 2-sided P value
Benzo[a]anthracene P/S −0.147/0.501 −/0.155 −/0.728 ns/0.05
Benzo[a]pyrene P/S −0.138/0.596 −/0.283 −/0.785 ns/0.0006
Benzo[b]ﬂuoranthene P/S −0.121/0.475 −/0.122 −/0.712 ns/0.009
Benzo[k]ﬂuoranthene P/S −0.111/0.116
Chrysene/triphenylene P/S −0.123/0.549 −/0.219 −/0.758 ns/0.002
Dibenzo[a,h]anthracene P/S −0.167/0.324
Indenol[1,2,3-cd]pyrene P/S −0.116/0.086
Acenaphthene P/S 0.397/0.348 0.028/− 0.662/− 0.03/ns
Acenaphthylene P/S 0.289/0.499 −/0.153 −/0.727 ns/0.005
Anthracene P/S 0.288/0.634 −/0.338 −/0.807 ns/0.0002
Benzo[ghi]perylene P/S −0.122/0.433 −/0.071 −/0.686 ns/0.01
Phenanthrene P/S 0.061/0.480 −/0.129 −/0.715 ns/0.008
Fluoranthene P/S 0.081/0.492 −/0.145 −/0.723 ns/0.006
Fluorene P/S 0.418/0.538 0.053/0.204 0.676/0.751 0.02/0.002
Naphthalene P/S 0.320/0.455 −/0.098 −/0.700 ns/0.01
Pyrene P/S 0.163/0.573 −/0.251 −/0.772 ns/0.001
PAH: polycyclic aromatic hydrocarbons, P: personal sampling, S: stationary sampling, ns: not signiﬁcant.
the same method and the same operating room have been
used, and the same personnel have been present. Addition-
ally, stationary samplings have been very precise due to the
possibility of attaching the ﬁlter within the smoke evacua-
tion hose. The smoke that was sucked into the hose was
collected 5cm from the electrocautery device, which should
concentrate and enhance the amount of smoke for analysis.
Consequently, personal samplings collected fewer kinds and
lesser amounts of PAHs than the stationary samplings,
perhaps as the personal ﬁlter was farther from the source of
the electrocautery smoke. This is the ﬁrst study to identify
and quantify USEPA’s 16 priority pollutant PAHs in electro-
cautery smoke during peritonectomy procedures. Regardless
of the duration of the peritonectomy procedures in this
study, low levels of PAHs were sampled. Consequently, the
hazard of adverse eﬀects from inhaling PAHs should be
minimal. Although long-term exposure to PAHs could lead
to high cumulative levels in surgeons and operating room
staﬀs, one should also consider the simultaneous exposures
of particles, PAHs, and volatile organic compounds, and that
there may be synergistic and additive eﬀects. More studies
are needed to evaluate the level, and the possible risk, of PAH
exposure in the operating room. Larger and selected study
groups seem to be necessary to increase the chance of signiﬁ-
cant ﬁndings.
5. Conclusions
Low levels of PAHs were detected in electrocautery smoke
during peritonectomy procedures. Naphthalene, which is
considered to be a possible carcinogen, was the most
abundant PAH in both personal and stationary samplings.
Only the amount of bleeding correlated with PAHs, which is
interesting in a larger perspective as the electrocautery device
is essential in almost all surgical interventions.
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